Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 11, 2007, Pages 1268-1285

  Ferrara, James L M ^a   Anasetti, Claudio ^b   Stadtmauer, Edward ^c   Antin, Joseph ^d   Wingard, John ^e   Lee, Stephanie ^f   Levine, John ^a   Schultz, Kirk ^g   Appelbaum, Frederick ^f   Negrin, Robert ^h   Giralt, Sergio ⁱ   Bredeson, Christopher ^j   Heslop, Helen ^k   Horowitz, Mary ^l  

^a UNIVERSITY OF MICHIGAN   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g BC CHILDREN S HOSPITAL   (Canada)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l CIBMTR   (United States)

more..

Author keywords

Acute lymphocytic leukemia; Acute myeloid leukemia; Biomarkers; Cell therapy; Chronic lymphocytic leukemia; Clinical trials; Clinical Trials Network; Crohn's disease; Graft versus host disease; Hemaphogocytic lymphohistiocytosis; Hematopoietic cell transplantation; Quality of life; T cell lymphoma

Indexed keywords

ANTILEUKEMIC AGENT; CARMUSTINE; CORTICOSTEROID; CYTARABINE; CYTOMEGALOVIRUS VACCINE; DASATINIB; DENILEUKIN DIFTITOX; ETANERCEPT; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 7; KERATINOCYTE GROWTH FACTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PNEUMOCOCCUS VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TOSITUMOMAB I 131; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD34 SELECTION; CELL THERAPY; CHILD HEALTH CARE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; CROHN DISEASE; EMOTIONALITY; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HIGH RISK POPULATION; HLA MATCHING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG FUNCTION TEST; LUNG TOXICITY; LYMPHOMA; MASS SCREENING; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASIA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REVIEW; SELF REPORT; STEM CELL MOBILIZATION; STRESS MANAGEMENT;

ADULT; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 35348912524     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.08.005     Document Type: Review

References (116)

1. Yanada M., Matsuo K., Emi N., and Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 103 (2005) 1652-1658
2. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
3. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 110 (2007) 409-417
4. Eapen M. Unrelated donor hematopoietic stem cell transplantation in children with acute leukemia: risks and benefits of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplantat 12 (2006) 21
5. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
6. Nieder M.L. Regimen-related toxicities after hematopoietic stem cell transplantation: managing the risks, treating the patients. ASCO Educational Book (2006), American Society of Clinical Oncology, Alexandria, VA 563-567
7. Afessa B., Litzow M.R., and Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 28 (2001) 425-434
8. Wadleigh M., Ho V., Momtaz P., and Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 10 (2003) 451-462
9. Yanik G., Hellerstedt B., Custer J., et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8 (2002) 395-400
10. Bogunia-Kubik K., Polak M., and Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplant. Bone Marrow Transplant 32 (2003) 617-622
11. Kallianpur A.R. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come?. Bone Marrow Transplant 35 (2005) 1-16
12. Hoh J., and Ott J. Mathematical multi-locus approaches to localizing complex human trait genes. Nat Rev Genet 4 (2003) 701-709
13. Zondervan K.T., and Cardon L.R. The complex interplay among factors that influence allelic association. Nat Rev Genet 5 (2004) 89-100
14. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73 (1989) 1729-1734
15. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
16. Beschorner W.E., Suresch D.L., Shinozawa T., Santos G.W., and Hess A.D. Thymic immunopathology after cyclosporine: effect of irradiation and age on medullary involution and recovery. Transplant Proc 20 (1988) 1072-1078
17. Shinozawa T., Beschorner W.E., and Hess A.D. The thymus and prolonged administration of cyclosporine. Transplant 50 (1990) 106-111
18. Kansu E., Gooley T., Flowers M.E., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 98 (2001) 3868-3870
19. Beschorner W.E., Hess A.D., Shinn C.A., and Santos G.W. Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation 45 (1988) 209-215
20. Santos G.W., Hess A.D., and Vogelsang G.B. Graft-versus-host reactions and disease. Immunol Rev 88 (1985) 169-192
21. Nguyen V.H., Zeiser R., Dasilva D.L., et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 109 (2007) 2649-2656
22. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., and Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11 (2005) 1244-1249
23. Xia G., Truitt R.L., and Johnson B.D. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 12 (2006) 397-407
24. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 7-12
25. Schultz K.R., Miklos D.B., Fowler D., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 12 (2006) 126-137
26. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
27. Anderson B.E., McNiff J.M., Jain D., Blazar B.R., Shlomchik W.D., and Shlomchik M.J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105 (2005) 2227-2234
28. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 353 (2005) 1321-1331
29. Seggewiss R., Lore K., Guenaga F.J., et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 110 (2007) 441-449
30. Rossi S., Blazar B.R., Farrell C.L., et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 100 (2002) 682-691
31. Min D., Taylor P.A., Panoskaltsis-Mortari A., et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 99 (2002) 4592-4600
32. Sutherland J.S., Goldberg G.L., Hammett M.V., et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175 (2005) 2741-2753
33. Shultz L.D., Lyons B.L., Burzenski L.M., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174 (2005) 6477-6489
34. Rosenberg S.A., Sportes C., Ahmadzadeh M., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29 (2006) 313-319
35. Alpdogan O., Eng J.M., Muriglan S.J., et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105 (2005) 865-873
36. Sun A., Wei H., Sun R., Xiao W., Yang Y., and Tian Z. Human interleukin-15 improves engraftment of human T cells in NOD-SCID mice. Clin Vaccine Immunol 13 (2006) 227-234
37. Meisel R., Kuypers L., Dirksen U., et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 109 (2007) 2322-2326
38. Antin J.H., Guinan E.C., Avigan D., et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 213-222
39. Molrine D.C., Antin J.H., Guinan E.C., et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 101 (2003) 831-836
40. Hata A., Asanuma H., Rinki M., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347 (2002) 26-34
41. Schleiss M.R., and Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4 (2005) 381-406
42. Landier W., Bhatia S., Eshelman D.A., et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22 (2004) 4979-4990
43. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 37 (2006) 249-261
44. Syrjala K.L., Donaldson G.W., Davis M.W., Kippes M.E., and Carr J.E. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain 63 (1995) 189-198
45. Dimeo F., Bertz H., Finke J., Fetscher S., Mertelsmann R., and Keul J. An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant 18 (1996) 1157-1160
46. Dimeo F., Fetscher S., Lange W., Mertelsmann R., and Keul J. Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood 90 (1997) 3390-3394
47. Dimeo F.C., Stieglitz R.D., Novelli-Fischer U., Fetscher S., and Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 85 (1999) 2273-2277
48. Hayes S., Davies P.S., Parker T., Bashford J., and Newman B. Quality of life changes following peripheral blood stem cell transplantation and participation in a mixed-type, moderate-intensity, exercise program. Bone Marrow Transplant 33 (2004) 553-558
49. Wilson R.W., Jacobsen P.B., and Fields K.K. Pilot study of a home-based aerobic exercise program for sedentary cancer survivors treated with hematopoietic stem cell transplantation. Bone Marrow Transplant 35 (2005) 721-727
50. Carlson L.E., Smith D., Russell J., Fibich C., and Whittaker T. Individualized exercise program for the treatment of severe fatigue in patients after allogeneic hematopoietic stem-cell transplant: a pilot study. Bone Marrow Transplant 37 (2006) 945-954
51. Filipovich A.H. Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol 6 (2006) 410-415
52. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 107 (2006) 1233-1236
53. Baker K.S., Eapen M., Gross T., et al. Unrelated donor hematopoietic cell transplant (HSCT) for hemophagocytic lymphohistiocytosis (HLH). Blood 108 (2006) 174
54. Marks D.I., Forman S.J., Blume K.G., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 12 (2006) 438-453
55. Brown V.I., Fang J., Alcorn K., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 100 (2003) 15113-15118
56. Teachey D.T., Obzut D.A., Cooperman J., et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107 (2006) 1149-1155
57. Blazar B.R., Krieg A.M., and Taylor P.A. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 98 (2001) 1217-1225
58. Reid G.S., She K., Terrett L., Food M.R., Trudeau J.D., and Schultz K.R. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood 105 (2005) 3641-3647
59. Fujii H., Trudeau J.D., Teachey D.T., et al. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood 109 (2007) 2008-2013
60. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 (2006) 460-466
61. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004) 4396-4407
62. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109 (2007) 1408-1413
63. Rowe J.M., Buck G., Fielding A., et al. In: adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). ASH Annu Meet Abstr 108 (2006) 2
64. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
65. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24 (2006) 444-453
66. Krauter J., Heil G., Hoelzer D., et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. ASH Annu Meet Abstr 106 (2005) 172
67. Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program (2006) 279-284
68. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3819-3829
69. Appelbaum F.R., and Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 Suppl 1 (1998) S25-S29
70. Field T., Perkins J., Alsina M., et al. Pretransplant 5-azacitidine may improve outcome of allogeneic hematopoietic cell transplantation in patients with myelodisplasia syndrome. Blood 108 (2006) 1047a
71. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
72. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 (2003) 4407-4412
73. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 3535-3542
74. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
75. Rizvi M.A., Evens A.M., Tallman M.S., Nelson B.P., and Rosen S.T. T-cell non-Hodgkin lymphoma. Blood 107 (2006) 1255-1264
76. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105 (2005) 2973-2978
77. The International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
78. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265
79. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
80. Pasquini MC. CIBMTR Summary Slides Part 1. 2005; Slides Part 1.
81. Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 82 (2007) 323-341
82. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
83. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 2220
84. Thomas E.D.B.K.G.F.S.J.A.F.R. Thomas' Hematopoietic Cell Transplantation. 3rd ed. (2004), Blackwell, Oxford xxvi, 1563
85. Elkin G., Prigozhina T.B., and Slavin S. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 32 (2004) 579-584
86. Griffith L.M., Pavletic S.Z., Tyndall A., et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 11 (2005) 862-870
87. Griffith L.M., Pavletic S.Z., Tyndall A., et al. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases-a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant 12 (2006) 688-690
88. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11 (2005) 389-398
89. Le Blanc K., and Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 18 (2006) 586-591
90. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 108 (2006) 1485-1491
91. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102 (2003) 2364-2372
92. Hough R.E., Snowden J.A., and Wulffraat N.M. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 128 (2005) 432-459
93. Nash R.A., McSweeney P.A., Crofford L.J., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110 (2007) 1388-1396
94. Oyama Y., Craig R.M., Traynor A.E., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128 (2005) 552-563
95. Leung Y., Geddes M., Storek J., Panaccione R., and Beck P.L. Hematopoietic cell transplantation for Crohn's disease; is it time?. World J Gastroenterol 12 (2006) 6665-6673
96. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12 (2006) 1160-1166
97. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 (2006) 1797-1808
98. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 (2005) 1123-1129
99. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007) 1123-1131
100. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
101. Molldrem J.J., Komanduri K., and Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 9 (2002) 503-508
102. Ciceri F., Bonini C., Marktel S., et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109 (2007) 4698-4707
103. Rettig M.P., Ritchey J.K., Prior J.L., Haug J.S., Piwnica-Worms D., and DiPersio J.F. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol 173 (2004) 3620-3630
104. Sadelain M., Riviere I., and Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3 (2003) 35-45
105. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
106. Horwitz E.M., Andreef M., and Frassoni F. Mesenchymal stromal cells. Biol Blood Marrow Transplant 13 (2007) 53-57
107. Sung N.S., Crowley Jr. W.F., Genel M., et al. Central challenges facing the national clinical research enterprise. JAMA 289 (2003) 1278-1287
108. Vickers A.J., Ballen V., and Scher H.I. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res 13 (2007) 972-976
109. Ratain M.J., and Karrison T.G. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res 13 (2007) 781-782
110. Van Glabbeke M., Steward W., and Armand J.P. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?. Eur J Cancer 38 (2002) 635-638
111. Rubinstein L.V., Korn E.L., Freidlin B., Hunsberger S., Ivy S.P., and Smith M.A. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23 (2005) 7199-7206
112. Ellenberg S.S., and Eisenberger M.A. An efficient design for phase III studies of combination chemotherapies. Cancer Treat Rep 69 (1985) 1147-1154
113. Inoue L.Y., Thall P.F., and Berry D.A. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58 (2002) 823-831
114. Schaid D.J., Ingle J.N., Wieand S., and Ahmann D.L. A design for phase II testing of anticancer agents within a phase III clinical trial. Control Clin Trials 9 (1988) 107-118
115. Storer B.E. A sequential phase II/III trial for binary outcomes. Stat Med 9 (1990) 229-235
116. Schaid D.J., Weiand S., and Therneau T.M. Optimal two-stage screening designs for survival comparisons. Biometrics 77 (1990) 507-513